A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination With Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (The RAP Trial).
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Everolimus (Primary) ; Ganitumab (Primary) ; Panitumumab (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Acronyms RAP
- 09 Feb 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 09 Feb 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 05 Jul 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2018.